BioSpace News Archive

The studies proposed in this grant aim to address several clinical challenges for dental implant therapy, especially in patients with low bone density conditions such as osteoporosis.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, demonstrating clinical activity at tolerable doses as a single agent across multiple tumor types.

Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX® (cabozantinib) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).

Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) today announced that it has closed the Share Exchange Agreement with PKG, Inc. (PKG) thereby having total control and ownership of PKG, Inc.

AB) today announced that an abstract on the long-term survival of masitinib in amyotrophic lateral sclerosis (ALS) has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurotlogy

Illumina Accelerator is a company creation engine that focuses on partnering with and building companies with unique genomic technologies.

Ventec Life Systems, a global medical device company focused on redefining respiratory care technologies for patients and caregivers announced today that the standalone V+Pro ventilator was added to the Pricing, Data Analysis and Coding (PDAC) Product Classification List (PCL) under the Health Care Procedure Coding System (HCPCS) as reimbursable under codes E0465 or E0466.

ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the firsthalfof 2021.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Cantor Virtual Global Healthcare Conference.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, is scheduled to participate in two upcoming investor conferences in September 2021.